XML 21 R7.htm IDEA: XBRL DOCUMENT v3.25.2
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) - USD ($)
$ in Thousands
3 Months Ended
Jul. 31, 2025
Jul. 31, 2024
Cash flows from operating activities:    
Net income $ 67,434 $ 64,256
Adjustments to reconcile net income to net cash used in operating activities:    
Depreciation and amortization 22,686 19,578
Stock-based compensation expense 11,009 10,783
Deferred income taxes 6,499 9,676
Provision for doubtful accounts 4,793 5,110
Gain on marketable securities (12,324) (14,185)
Gain on cash surrender value of life insurance policies (2,569) (2,246)
Change in other assets and liabilities:    
Deferred compensation 27,763 22,938
Receivables due from clients (39,900) (37,115)
Income taxes and other receivables (8,539) (9,003)
Prepaid expenses and other assets (16,825) (7,023)
Unearned compensation (20,236) (16,386)
Income taxes payable 125 (964)
Accounts payable and accrued liabilities (276,906) (272,117)
Other (377) (487)
Net cash used in operating activities (237,367) (227,185)
Cash flows from investing activities:    
Purchase of property and equipment (22,599) (10,497)
Purchase of marketable securities (9,630) (11,181)
Proceeds from sales/maturities of marketable securities 13,543 8,351
Proceeds from life insurance policies 7 93
Premium on company-owned life insurance policies (13,502) (13,502)
Net cash used in investing activities (32,181) (26,736)
Cash flows from financing activities:    
Dividends paid to stockholders (26,209) (19,800)
Repurchases of common stock (10,298) (23,488)
Payments of tax withholdings on restricted stock (18,704) (16,625)
Proceeds from issuance of common stock in connection with an employee stock purchase plan 4,158 4,248
Principal payments on finance leases (499) (412)
Net cash used in financing activities (51,552) (56,077)
Effect of exchange rate changes on cash and cash equivalents (1,009) 2,369
Net decrease in cash and cash equivalents (322,109) (307,629)
Cash and cash equivalents at beginning of period 1,006,964 941,005
Cash and cash equivalents at end of the period $ 684,855 $ 633,376